Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Payables (2019 - 2025)

Historic Payables for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $4.1 million.

  • aTYR PHARMA's Payables rose 291.21% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 291.21%. This contributed to the annual value of $4.3 million for FY2024, which is 2249.93% up from last year.
  • Latest data reveals that aTYR PHARMA reported Payables of $4.1 million as of Q3 2025, which was up 291.21% from $3.9 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Payables high stood at $4.9 million for Q1 2024, and its period low was $516000.0 during Q2 2023.
  • Over the past 5 years, aTYR PHARMA's median Payables value was $2.2 million (recorded in 2021), while the average stood at $2.6 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 26882.26% in 2021, then tumbled by 6917.56% in 2023.
  • aTYR PHARMA's Payables (Quarter) stood at $1.0 million in 2021, then surged by 201.26% to $3.1 million in 2022, then increased by 13.62% to $3.5 million in 2023, then increased by 22.5% to $4.3 million in 2024, then fell by 5.99% to $4.1 million in 2025.
  • Its Payables stands at $4.1 million for Q3 2025, versus $3.9 million for Q2 2025 and $1.5 million for Q1 2025.